跳至主要内容
临床试验/NCT04105985
NCT04105985撤回2 期

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial

Virginia Commonwealth University0 个研究点开始时间: 2020年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
主要终点
Success rate of pupal anesthesia

研究概览

简要总结

The primary goal of the study is to compare the success rates of pulpal anesthesia (defined as ability to complete the intended dental procedure without the need for rescue anesthesia) between Kovanaze nasal mist and Articaine needle anesthesia.

详细描述

In June 2016, an intranasal delivery system of local anesthesia called Kovanaze, gained FDA approval. [9] Kovanaze is available as a 0.2 ml metered spray and is intended to achieve pulpal anesthesia of 5 maxillary teeth on either side of the face.

With the ability to avoid the traditional painful injection Kovanaze offers promise in the field of maxillary anesthesia and this study intends to:

  1. Compare Kovanaze to conventional needle anesthetic for procedures other than fillings and/or involving multiple teeth in adults
  2. Evaluate patient anxiety, tolerance and acceptability of Kovanaze in patients undergoing dental procedures

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • American Society of Anesthesiologists Class I or II
  • Preoperative heart rate of 55 to 100 beats per minute
  • Maximum blood pressure reading of 166/100 mmHg
  • Treatment for a pathology in the maxillary anterior tooth or premolar that requires administering local anesthesia
  • Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth

排除标准

  • Inadequately controlled thyroid disease
  • Five or more nosebleeds in the past month
  • Known allergy to any study drug or para-aminobenzoic acid
  • History of methemoglobinemia
  • Taking monoamine oxidase inhibitors, tricyclic antidepressants (i.e. amitriptyline), or non-selective beta adrenergic antagonists (i.e. propranolol);
  • Taking oxymetazoline-containing products (i.e., Afrin) in the last 24 hours.

研究组 & 干预措施

Kovanaze Nasal Spray (endodontics)

Experimental

Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth

干预措施: Kovanaze Nasal Spray (Drug)

Articaine Injections (endodontics)

Active Comparator

Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth

干预措施: Articaine Injection (Drug)

结局指标

主要结局

Success rate of pupal anesthesia

时间窗: immediately after dental procedure, an average of 3 hours

% dental procedures completed without the need for rescue anesthesia

次要结局

  • Spread of anesthesia(immediately after dental procedure, an average of 3 hours)
  • Change in Anxiety level(from baseline to immediately after dental procedure)
  • Change in Blood pressure(from baseline to immediately after dental procedure)
  • Change in heart rate(from baseline to immediately after dental procedure)
  • Change in pain(from baseline to immediately after dental procedure)
  • Satisfaction with Kovanaze(immediately after dental procedure, an average of 3 hours)
  • Number of post treatment anesthesia side effects(24 hours)

研究者

申办方类型
Other
责任方
Sponsor

相似试验